Ardsley Advisory Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ardsley Advisory Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-110,450	Closed	-$9.19M	–	156
2022 Q4	$9.19M	Buy	110,450 +35,000	+46%	+$2.83M	1.9%	21
2022 Q3	$6M	Buy	+75,450	New	+$6.36M	1.34%	25
2022 Q2	–	Sell	-135,000	Closed	-$10.1M	–	176
2022 Q1	$12.1M	Buy	135,000 +45,000	+50%	+$4.16M	2.02%	11
2021 Q4	$10.1M	Buy	+90,000	New	+$10.9M	1.92%	17
2020 Q3	–	Sell	-4,850	Closed	-$543K	–	183
2020 Q2	$543K	Sell	4,850 -90,150	-95%	-$8.88M	0.12%	83
2020 Q1	$7.36M	Sell	95,000 -15,000	-14%	-$1.33M	2.88%	12
2019 Q4	$10.5M	Buy	+110,000	New	+$9.51M	1.67%	20
2019 Q3	–	Sell	-7,500	Closed	-$658K	–	179
2019 Q2	$658K	Sell	7,500 -57,500	-88%	-$4.9M	0.1%	81
2019 Q1	$5.88M	Buy	65,000 +60,500	+1,344%	+$5.15M	1.13%	29
2018 Q4	$323K	Sell	4,500 -2,500	-36%	-$201K	0.08%	81
2018 Q3	$671K	Sell	7,000 -105,000	-94%	-$10.2M	0.09%	85
2018 Q2	$10.7M	Sell	112,000 -126,500	-53%	-$11.6M	1.6%	22
2018 Q1	$20.9M	Sell	238,500 -39,000	-14%	-$3.56M	3.14%	5
2017 Q4	$23.5M	Buy	277,500 +9,500	+4%	+$796K	2.86%	6
2017 Q3	$23.2M	Sell	268,000 -8,000	-3%	-$641K	3.09%	6
2017 Q2	$21.3M	Buy	276,000 +56,500	+26%	+$4.01M	3.32%	6
2017 Q1	$15.2M	Buy	219,500 +212,000	+2,827%	+$14.2M	2.36%	10
2016 Q4	$444K	Sell	7,500 -2,500	-25%	-$154K	0.07%	91
2016 Q3	$663K	Buy	10,000 +3,000	+43%	+$186K	0.1%	85
2016 Q2	$379K	Sell	7,000 -3,000	-30%	-$164K	0.07%	93
2016 Q1	$517K	Buy	10,000 +5,000	+100%	+$260K	0.08%	79
2015 Q4	$351K	Buy	+5,000	New	+$341K	0.05%	97
2014 Q2	–	Sell	-7,500	Closed	-$356K	–	296
2014 Q1	$356K	Buy	+7,500	New	+$384K	0.05%	166

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ardsley Advisory Partners's XBI Position: Q1 2023 in Review

Ardsley Advisory Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 110,450 shares — an estimated $9.19M sold.

Ardsley Advisory Partners first reported a position in XBI in Q1 2014 and held it in 23 quarters. The position peaked at $23.5M in Q4 2017. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Ardsley Advisory Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
Ardsley Advisory Partners sold 110,450 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $9.19M.
Ardsley Advisory Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and held it in 23 quarters.
Ardsley Advisory Partners's State Street SPDR S&P Biotech ETF position peaked at $23.5M in Q4 2017.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Ardsley Advisory Partners's 13F filing for Q1 2023, filed 15 May 2023.